[go: up one dir, main page]

AR121811A2 - PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS - Google Patents

PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS

Info

Publication number
AR121811A2
AR121811A2 ARP210100948A ARP210100948A AR121811A2 AR 121811 A2 AR121811 A2 AR 121811A2 AR P210100948 A ARP210100948 A AR P210100948A AR P210100948 A ARP210100948 A AR P210100948A AR 121811 A2 AR121811 A2 AR 121811A2
Authority
AR
Argentina
Prior art keywords
peptides
lymphocyte
peptide
antibody
kit
Prior art date
Application number
ARP210100948A
Other languages
Spanish (es)
Inventor
Mahr Andrea Dr
Weinschenk Toni Dr
Schoor Oliver Dr
Jens Fritsche
Singh Harpreet Dr
Stevermann Lea Dr
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of AR121811A2 publication Critical patent/AR121811A2/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con péptidos, proteínas, ácidos nucleicos y células para su uso en métodos inmunoterapéuticos. En particular, la presente invención se relaciona con inmunoterapia para el cáncer. La presente invención se relaciona además con epitopes de péptidos de células T asociados con tumores, solos o en combinación con otros péptidos asociados con tumores que pueden, por ejemplo, servir como ingredientes farmacéuticos activos de composiciones para vacunas que estimulan la respuesta inmune antitumoral o para estimular células T ex vivo y transferirlas a pacientes. Los péptidos unidos a moléculas del complejo de histocompatibilidad principal (MHC) o los péptidos como tales también pueden ser el blanco de anticuerpos, receptores de células T solubles y otras moléculas de unión.The present invention relates to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, the present invention relates to immunotherapy for cancer. The present invention further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can, for example, serve as active pharmaceutical ingredients of compositions for vaccines that stimulate antitumor immune response or for stimulate T cells ex vivo and transfer them to patients. Peptides bound to major histocompatibility complex (MHC) molecules or peptides themselves can also be targeted by antibodies, soluble T-cell receptors, and other binding molecules.

ARP210100948A 2015-03-27 2021-04-09 PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS AR121811A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562139189P 2015-03-27 2015-03-27

Publications (1)

Publication Number Publication Date
AR121811A2 true AR121811A2 (en) 2022-07-13

Family

ID=59256464

Family Applications (7)

Application Number Title Priority Date Filing Date
ARP160100818A AR104113A1 (en) 2015-03-27 2016-03-28 PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
ARP180102260A AR112781A2 (en) 2015-03-27 2018-08-08 PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
ARP210100947A AR121810A2 (en) 2015-03-27 2021-04-09 PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS
ARP210100945A AR121809A2 (en) 2015-03-27 2021-04-09 PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS
ARP210100948A AR121811A2 (en) 2015-03-27 2021-04-09 PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS
ARP210100949A AR121812A2 (en) 2015-03-27 2021-04-09 PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS
ARP210102531A AR123493A2 (en) 2015-03-27 2021-09-13 PEPTIDE, NUCLEIC ACID, EXPRESSION VECTOR, RECOMBINANT HOST CELL, ANTIBODY, KIT, PHARMACEUTICAL COMPOSITION AND RELATED METHODS

Family Applications Before (4)

Application Number Title Priority Date Filing Date
ARP160100818A AR104113A1 (en) 2015-03-27 2016-03-28 PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
ARP180102260A AR112781A2 (en) 2015-03-27 2018-08-08 PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
ARP210100947A AR121810A2 (en) 2015-03-27 2021-04-09 PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS
ARP210100945A AR121809A2 (en) 2015-03-27 2021-04-09 PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP210100949A AR121812A2 (en) 2015-03-27 2021-04-09 PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS
ARP210102531A AR123493A2 (en) 2015-03-27 2021-09-13 PEPTIDE, NUCLEIC ACID, EXPRESSION VECTOR, RECOMBINANT HOST CELL, ANTIBODY, KIT, PHARMACEUTICAL COMPOSITION AND RELATED METHODS

Country Status (1)

Country Link
AR (7) AR104113A1 (en)

Also Published As

Publication number Publication date
AR104113A1 (en) 2017-06-28
AR121810A2 (en) 2022-07-13
AR121812A2 (en) 2022-07-13
AR123493A2 (en) 2022-12-07
AR112781A2 (en) 2019-12-11
AR121809A2 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
AR127119A2 (en) NOVEL PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
CL2023001346A1 (en) Use of peptides in immunotherapy against small cell lung cancer and others.
CO2018003659A2 (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other types of cancer
MX2023014146A (en) Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers.
CR20200592A (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
PE20230768A1 (en) NOVEL PEPTIDES AND NEW PEPTIDE COMBINATIONS FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING SMALL CELL LUNG CANCER AND OTHER CANCERS
CR20200495A (en) NEW PEPTIDES, PEPTIDE COMBINATIONS AND SUPPORTS FOR USE IN THE IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS TYPES OF CANCER (Divisional 2018-174)
MX2020012777A (en) NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS TO CREATE SUPPORTS FOR USE AGAINST PANCREATIC CANCER AND OTHER TYPES OF CANCER.
CR20220115A (en) NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (Div. 2017-522)
CR20180001A (en) NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER TYPES OF CANCER.
CR20200561A (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
MX2017011857A (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers.
CR20180051A (en) NEW CELLULAR EPITHOPES AND NEW COMBINATIONS OF CELLULAR EPITHOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER TYPES OF CANCER.
AR121024A2 (en) PEPTIDE, ENCODING NUCLEIC ACID, ANTIBODY, T-LYMPHOCYTE, T-LYMPHOCYTE RECEPTOR, APTAMER, RECOMBINANT HOST CELL, PHARMACEUTICAL COMPOSITION AND EQUIPMENT
CR20210128A (en) NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER TYPES OF CANCER (DIVISIONAL EXP. 2019-388)
CR20210068A (en) NEW PEPTIDES AND SUPPORT STRUCTURES FOR USE IN IMMUNOTHERAPY AGAINST EPIDERMOID CARCINOMA OF THE HEAD AND NECK AND OTHER CANCER (Divisional 2019-0094)
CR20200639A (en) NEW PEPTIDES AND NEW COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA, AS WELL AS OTHER TYPES OF CANCER (Divisional 2018-0591)
MX2019012226A (en) Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers.
MX2022002263A (en) NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES AND SUPPORTS FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA AND OTHER TYPES OF CANCER.
MX2022005570A (en) NEW PEPTIDES AND NEW COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREAS CANCER AND OTHER TYPES OF CANCER.
CO2018000247A2 (en) New cell epitopes and new combinations of cell epitopes for use in the immunotherapy of myeloma and other types of cancer
AR121812A2 (en) PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS
MX2022000201A (en) NEW PEPTIDES AND NEW COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA, AS WELL AS OTHER TYPES OF CANCER.
CR20170522A (en) PEPTIDES AND COMBINATION OF NOVELED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal